- Home
- CGNT vs PRTA Comparison
CGNT vs PRTA Comparison
Compare CGNT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- PRTA
- Stock Information
- Founded
- CGNT 2020
- PRTA 2012
- Country
- CGNT Israel
- PRTA Ireland
- Employees
- CGNT N/A
- PRTA N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- PRTA Health Care
- Exchange
- CGNT Nasdaq
- PRTA Nasdaq
- Market Cap
- CGNT 743.4M
- PRTA 765.2M
- IPO Year
- CGNT N/A
- PRTA N/A
- Fundamental
- Price
- CGNT $9.14
- PRTA $15.56
- Analyst Decision
- CGNT Hold
- PRTA Buy
- Analyst Count
- CGNT 3
- PRTA 8
- Target Price
- CGNT $8.25
- PRTA $46.00
- AVG Volume (30 Days)
- CGNT 288.0K
- PRTA 307.4K
- Earning Date
- CGNT 04-08-2025
- PRTA 02-20-2025
- Dividend Yield
- CGNT N/A
- PRTA N/A
- EPS Growth
- CGNT N/A
- PRTA N/A
- EPS
- CGNT N/A
- PRTA N/A
- Revenue
- CGNT $339,818,000.00
- PRTA $135,157,000.00
- Revenue This Year
- CGNT $13.67
- PRTA $56.89
- Revenue Next Year
- CGNT $6.92
- PRTA N/A
- P/E Ratio
- CGNT N/A
- PRTA N/A
- Revenue Growth
- CGNT 12.16
- PRTA 47.92
- 52 Week Low
- CGNT $6.21
- PRTA $11.70
- 52 Week High
- CGNT $11.12
- PRTA $31.03
- Technical
- Relative Strength Index (RSI)
- CGNT 38.71
- PRTA 59.65
- Support Level
- CGNT $10.52
- PRTA $13.69
- Resistance Level
- CGNT $10.91
- PRTA $15.09
- Average True Range (ATR)
- CGNT 0.43
- PRTA 0.91
- MACD
- CGNT -0.17
- PRTA 0.13
- Stochastic Oscillator
- CGNT 13.54
- PRTA 68.56
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).